Untapped potential: recognising CNS opportunities in early oncology drug development
- PMID: 31587879
- DOI: 10.1016/S1470-2045(19)30633-3
Untapped potential: recognising CNS opportunities in early oncology drug development
Comment on
-
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
